STOCK TITAN

Pasithea plans PAS-004 Phase 2 trial in about 200 adults

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Pasithea Therapeutics Corp. (KTTA) reported initial PAS-004 results from its ongoing Phase 1/1b study in adults with NF1 and said the FDA cleared its IND for a Phase 2 trial in cutaneous neurofibromas (cNF). Among 15 evaluable cNF participants, median best reduction in summed target-lesion surface area was 41%; among eight participants at 4, 8 and 12 mg, it was 46%. In the 4 mg cohort, median reduction reached 71% at Cycle 15.

All 18 participants evaluable for plexiform neurofibroma (PN) showed target tumor-volume reductions by blinded independent central review; two met the REiNS partial-response threshold. One had a 22.5% reduction at the first on-treatment MRI, pending confirmation on a subsequent scan. The planned Phase 2 trial will evaluate three once-daily doses in approximately 200 adults in a randomized, double-blind, placebo-controlled study. Pasithea reported no treatment-related serious adverse events; two Grade 3 treatment-related events were asymptomatic CPK increases that resolved after a one-week dose interruption.

Item 7.01 Regulation FD Disclosure Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Median best cNF surface-area reduction 41% Among 15 evaluable participants
Median best cNF surface-area reduction at 4, 8 and 12 mg 46% Among eight evaluable participants
Median cNF surface-area reduction 71% 4 mg cohort at Cycle 15
Participants meeting PN partial-response threshold 2 participants Among 18 evaluable participants; responses at 12 mg and 15 mg
PN volume reduction at first on-treatment MRI 22.5% One participant at 15 mg; pending confirmation on a subsequent scan
Treatment-related Grade 1 or 2 adverse events 97.6% of events As reported in the safety data
Terminal half-life 40 to 60 hours PAS-004 pharmacokinetics
Planned Phase 2 trial enrollment Approximately 200 adults Adults with NF1-associated cNF
REiNS partial-response threshold medical
"met the REiNS partial-response threshold"
blinded independent central review medical
"by blinded independent central review"
Blinded independent central review is a quality-control step in clinical trials where outside medical experts, who do not know which patients received the experimental therapy, re-examine key measurements (like scans or lab results) to prevent bias. Think of it as neutral referees watching game footage without knowing the teams, which gives investors greater confidence that the trial results are fair, more reliable for regulators, and less likely to be overturned or disputed.
pharmacokinetics medical
"assesses safety, tolerability, pharmacokinetics and pharmacodynamics"
Pharmacokinetics is the study of how a substance, such as a drug or chemical, moves through and is processed by the body over time. It tracks how it is absorbed, distributed, broken down, and eventually eliminated. For investors, understanding pharmacokinetics helps gauge the effectiveness, safety, and potential risks of new medications or treatments, which can influence a company’s success and valuation in the healthcare industry.
terminal half-life medical
"a terminal half-life of 40 to 60 hours"
Terminal half-life is the time it takes for the amount of a drug in the body to fall by half during the final, slow phase of its elimination — like how long a slowly leaking tank takes to lose half its water. Investors care because it shapes how often patients must take the drug, how long effects and side effects last, and therefore influences dosing convenience, trial length, safety profiles and commercial attractiveness.
Investigational New Drug application regulatory
"cleared the Company’s Investigational New Drug application"
An investigational new drug application is a formal request made to regulatory authorities to begin testing a new medication in humans. It is a critical step in the drug development process, as approval indicates the drug has passed initial safety checks and can be studied further. For investors, this signals that a potential new treatment is progressing through its early testing stages, which can impact the company's future growth prospects.
Cmax/Cmin technical
"Cmax/Cmin of 1.5 to 2.0"
Cmax and Cmin are pharmacokinetic measurements of a drug’s concentration in blood or plasma: Cmax is the highest concentration reached after a dose (the peak), and Cmin is the lowest concentration reached during the dosing interval, typically the trough measured just before the next dose. They are measured at specific times after dosing, depend on absorption, distribution and clearance, and change between a single dose and steady‑state repeated dosing; Cmax and Cmin are used to describe exposure but do not by themselves measure clinical effect or safety.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What cNF reductions did KTTA report with PAS-004?

Among 15 evaluable participants, the median best reduction in summed target cNF surface area was 41%. For eight participants treated at 4, 8 and 12 mg, the median best reduction was 46%; all six participants treated at 4 mg and 8 mg had reductions greater than 40%.

What did KTTA report about PAS-004 in plexiform neurofibromas?

All 18 evaluable participants showed reductions in target PN volume. Two participants met the REiNS partial-response threshold, at 12 mg and 15 mg. The participant at 15 mg had a 22.5% reduction at the first on-treatment MRI, pending confirmation on a subsequent scan.

What safety findings did KTTA report for PAS-004?

Pasithea reported no treatment-related serious adverse events, treatment-related discontinuations, adverse events of decreased LVEF, or cases of retinopathy. Most treatment-related adverse events were Grade 1 or 2 (97.6% of events). Two Grade 3 events were asymptomatic CPK increases; both resolved after a one-week dose interruption, and both participants continued treatment.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0001841330 0001841330 2026-11-13 2026-11-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 13, 2026

 

Pasithea Therapeutics Corp.

(Exact name of registrant as specified in its charter)

 

Delaware   001-40804   85-1591963
(State or other jurisdiction
of incorporation)
  (Commission File Number)   (IRS Employer
Identification No.)

 

1111 Lincoln Road, Suite 500

Miami Beach, Florida

  33139
(Address of principal executive offices)   (Zip Code)

 

(786) 977-3380

(Registrant’s telephone number, including area code)

 

N/A

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.0001 per share   KTTA   The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 7.01 Regulation FD

 

On November 13, 2026, Pasithea Therapeutics Corp. (the “Company”) issued a press release announcing initial clinical data from its ongoing Phase 1/1b study of PAS-004 in adults with neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas and cutaneous neurofibromas, which data were presented at the 2026 European Neurofibromatosis Conference. The press release also announced that the U.S. Food and Drug Administration has cleared the Company’s Investigational New Drug application for a Phase 2 trial of PAS-004 in adults with NF1-associated cutaneous neurofibromas. The Company also posted a webcast on November 13, 2026 to discuss the data described in the November Press Release. A replay of the webcast is accessible at https://viavid.webcasts.com/viewer/event.jsp?ei=1782843&tp_key=e4a54fdcc4. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

 

The information in this Current Report on Form 8-K under Item 7.01, including the information contained in Exhibit 99.1, is being furnished to the Securities and Exchange Commission (the “SEC”), and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by a specific reference in such filing.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.   Description
99.1   Press Release dated November 13, 2026.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

1

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  PASITHEA THERAPEUTICS CORP.
     
Date: November 16, 2026 By: /s/ Tiago Reis Marques
  Name: Tiago Reis Marques
  Title: Chief Executive Officer

 

2

 

Exhibit 99.1

 

 

 

Pasithea Therapeutics Presents Positive Initial Phase 1/1b Data for PAS-004, Showing Substantial Reductions in Cutaneous Neurofibroma Size and Early Activity in Plexiform Neurofibromas at the 2026 European Neurofibromatosis Conference

 

●All participants showed cutaneous neurofibroma (cNF) reductions: All 15 evaluable participants had reductions in target cNF surface area, with a median best reduction of 41% across all doses and 46% at doses planned for Phase 2

 

●cNF reductions deepened with continued treatment: The median reduction in target cNF surface area reached 49% at Cycle 12 among participants followed through 12 cycles and 71% at Cycle 15 in the 4mg cohort

 

●Favorable safety and tolerability profile: No treatment related serious adverse events, treatment related discontinuations, retinopathy or adverse event of decreased left ventricular ejection fraction (LVEF)

 

●IND cleared for Phase 2 in cNF: The FDA’s Division of Dermatology and Dentistry has cleared the IND for a Phase 2 trial of PAS-004 in adults with NF1-associated cNF

 

●Early activity in plexiform neurofibromas (PN): Reductions in target PN volume observed in all 18 evaluable participants, including two with reductions ≥20%, one achieving a 22.5% reduction at the first on-treatment MRI (Cycle 4)

 

●PAS-004 Clinical Data Webcast: Pasithea will post a webcast on Friday, November 13, 2026, at 7:00 a.m. EST to discuss the data presented at the European Neurofibromatosis Conference

 

MIAMI, FL., November 13, 2026 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor, today announced positive clinical data from its ongoing Phase 1/1b study in adults with neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas (PN) and a subset of patients with cutaneous neurofibromas (cNF) (Study PAS-004-103, NCT06961565), presented at the 2026 European Neurofibromatosis Conference in Vienna, Austria.

 

“Cutaneous neurofibromas do not regress spontaneously and generally increase in number and size with age. The substantial reductions in cNF size reported today represent an encouraging clinical signal in a condition for which there are currently no FDA-approved systemic treatments,” said Dr. Tiago Reis Marques, Chief Executive Officer of Pasithea. “Importantly, these reductions have continued to deepen with longer treatment, including at the lowest doses tested. With our IND now cleared by FDA’s Division of Dermatology and Dentistry, these findings reinforce our confidence in the 4mg to 12mg dose range planned for Phase 2 and support advancing PAS-004 into a randomized, placebo-controlled study in cNF.”

 

 

 

“The reductions in cNF size observed with oral PAS-004 highlight its potential to provide broad, visible improvements for patients through a systemic treatment approach, rather than relying on local procedures that can treat individual lesions,” said Dr. Kartik Krishnan, Chief Medical Officer of Pasithea. “We are also seeing early activity in plexiform neurofibromas, with reductions in tumor volume across all dose levels and two participants meeting the REiNS threshold for partial response, including one at the first on-treatment MRI. Together with the favorable tolerability observed to date and a pharmacokinetic profile characterized by a 40-to-60-hour half-life and limited peak-to-trough fluctuations, these findings support the continued development of PAS-004 as a once-daily oral therapy for long-term treatment of NF1-associated neurofibromas.”

 

Pasithea will post a webcast on Friday, November 13, 2026, at 7:00 a.m. EST to discuss the PAS-004 clinical data presented at the 2026 European Neurofibromatosis Conference. The webcast will be accessible here and through the Investors section of the Company’s website.

 

Study Overview

 

Study PAS-004-103 is an ongoing multicenter, open-label Phase 1/1b trial in adults with NF1 and symptomatic and inoperable, incompletely resected, or recurrent PN at five sites in the United States, Australia and South Korea. The study also evaluates up to 7 cNFs in participants with measurable lesions. Part A studies six escalating doses using a 3+3 design to select two doses for evaluation in Part B, a randomized dose expansion phase. The study also assesses safety, tolerability, pharmacokinetics and pharmacodynamics.

 

As of September 15, 2026, 19 participants have been enrolled across six cohorts (4, 8, 12, 15, 18 and 24mg). Of these, 15 were evaluable for cNF and 18 for PN response. Median treatment duration ranged from 14.4 months at 4mg to approximately 4 months at 15mg and 24mg. One participant discontinued by sponsor decision for noncompliance, unrelated to safety.

 

Cutaneous Neurofibroma (cNF) Data

 

Fifteen participants were evaluable for cNF, with 71 target cNFs measured at baseline. Length and width of each target cNF were measured in triplicate with digital calipers. As there is no regulatory standard for assessing cNFs, both surface area (calculated from length and width) and longest diameter (the REiNS-recommended caliper measure) are reported.

 

Substantial Reductions in cNF Surface Area (Figure 1)

 

Reductions Across All Doses: All 15 evaluable participants showed reductions in summed target cNF surface area at best response, with a median best reduction of 41%.

 

Activity at Planned Phase 2 Doses: Among eight evaluable participants treated at 4, 8 and 12mg, the median best reduction was 46%. All six participants treated at 4mg and 8mg achieved reductions greater than 40%.

 

 

Figure 1: Best change from baseline in summed target cNF surface area by participant, grouped by dose cohort (N = 15). Data cut-off October 7, 2026.

 

2

 

 

cNF Reductions Deepened with Continued Treatment (Figure 2)

 

Among participants followed through 12 treatment cycles, the median reduction in summed target cNF surface area increased from 12% at Cycle 1 to 38% at Cycle 4 and 49% at Cycle 12. In the 4mg cohort, the median reduction reached 71% at Cycle 15.

 

 

Figure 2. Change in summed target cNF surface area over time by participant and dose cohort. Dashed lines indicate 20% and 37% reduction thresholds (37% area ≈ 50% volume). Data cut-off: October 7, 2026.

 

Consistent Findings Using Longest-Diameter Measurements (Figure 3)

 

At the 4, 8 and 12mg doses planned for the Phase 2 trial, 27 of 37 target cNFs (73%) were reduced by at least 25% in longest diameter, meeting the REiNS shrinkage criterion. Eight of the 37 target cNFs were surgically resected (red ovals) for pharmacodynamic analysis at either Cycle 1 or Cycle 6 and could not be assessed thereafter; they are included with their last measurement before resection. Among the 29 cNFs that were not resected, 24 (83%) met the REiNS criterion, with a median best reduction in longest diameter of 39%.

 

 

 

Figure 3. Best change in target cNF longest diameter at 4, 8 and 12mg (37 target cNF from 8 participants). Red ovals identify the target cNF resected for pharmacodynamic analysis; dashed line indicates the REiNS 25% shrinkage threshold. Data cut-off: October 7, 2026.

 

3

 

 

Early Activity in Plexiform Neurofibromas (Figure 4)

 

All 18 evaluable participants showed reductions in target PN volume by blinded independent central review, including two who met the REiNS partial-response threshold at 12mg and 15mg. The 15mg participant achieved a 22.5% reduction at the first on-treatment MRI, pending confirmation on a subsequent scan.

 

 

Figure 4. Best change in target PN volume by participant and dose cohort, based on blinded independent central review (N = 18). Dashed line indicates the REiNS 20% partial-response threshold. MRI data cut-off September 30, 2026.

 

Safety and Tolerability

 

No treatment-related serious adverse events, discontinuations, adverse events of decreased LVEF, or cases of retinopathy have been reported. Most treatment-related adverse events were Grade 1 or 2 (97.6% of events). The two Grade 3 treatment-related events were asymptomatic increases in blood creatine phosphokinase (CPK), both of which resolved following a one-week dose interruption, with both participants continuing treatment. At the 4 to 12mg doses planned for Phase 2, dermatitis acneiform (rash) and diarrhea occurred in 33% and 11% of participants, respectively (data cut-off: September 15, 2026).

 

Pharmacokinetics

 

PAS-004 showed approximately dose-proportional exposure across the 4 to 24mg range, a terminal half-life of 40 to 60 hours, and limited peak-to-trough fluctuations (Cmax/Cmin of 1.5 to 2.0), consistent with findings from the Company’s ongoing Phase 1 study in advanced solid tumors and supporting once-daily dosing (data cut-off: October 7, 2026).

 

4

 

 

Next Steps

 

The FDA’s Division of Dermatology and Dentistry has cleared the IND for Study PAS-004-201, a randomized, double-blind, placebo-controlled Phase 2 trial evaluating three once-daily doses of PAS-004 in approximately 200 adults with NF1-associated cNF.

 

The ongoing Phase 1/1b study (PAS-004-103) will continue participant follow-up and advance toward Part B, a randomized two-dose expansion phase. The Company expects to complete pharmacodynamic analyses of resected cNFs in 2027 and present additional clinical data at future scientific meetings.

 

About Cutaneous Neurofibromas (cNF)

 

NF1-associated cutaneous neurofibromas (cNFs) are benign tumors that grow in or just beneath the skin at virtually any location in the body and are a hallmark of NF1. It is a serious condition and cNFs are associated with significant morbidity that can have substantial impact on day-to-day functioning, leading patients to rate this as the most significant burden of NF1 despite other potentially life-threatening complications. cNF typically begin to appear in adolescence, generally increase in number and volume with age. The number of cNFs on an individual patient can range from a few to thousands. Although malignant transformation does not occur with NF1-associated cNF, cNFs are present in over 95% of individuals with NF1 and have a significant negative impact both physically, with disfigurement, and on health-related quality of life. Current management relies largely on procedural approaches such as surgical excision, electrodesiccation, or laser therapy. There are no FDA-approved systemic therapies for the treatment of NF1-associated cNF.

 

About Plexiform Neurofibromas (PN)

 

NF1-associated plexiform neurofibromas (PNs) are tumors originating from the nerve sheath that grow through and around nerves and may involve multiple nerve branches. Thirty to fifty percent (30-50%) of patients with NF1 will harbor PNs, which can undergo malignant transformation. PN-related morbidities, including pain, disfigurement and functional impairment are primarily caused by the direct impact of the tumor on surrounding structures and can be life-threatening when they compress vital organs or when they become malignant.

 

About Pasithea Therapeutics Corp.

 

Pasithea is a clinical-stage biotechnology company primarily focused on the research and development of its lead drug candidate, PAS-004, a next-generation macrocyclic MEK inhibitor intended for the treatment of RASopathies, MAPK pathway-driven tumors, and other diseases. The Company is currently testing PAS-004 in a Phase 1 clinical trial in advanced cancer patients (NCT06299839), and a Phase 1/1b clinical trial in adult patients with neurofibromatosis type 1 (NF1)-associated cutaneous and plexiform neurofibromas (NCT06961565).

 

5

 

 

Forward Looking Statements

 

This press release contains statements that constitute “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding the Company’s clinical data from Study PAS-004-103 in cNF and PN, including response rates, durability, and safety observations, and their significance, the Company’s planned Phase 2 study of PAS-004 in cNF and the FDA’s clearance of the Company’s IND to proceed with such study, the Company’s clinical data from its Phase 1 dose-escalation study of PAS-004 in advanced solid tumors, and the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) and preliminary efficacy of PAS-004, as well as all other statements, other than statements of historical fact, regarding the Company’s current views and assumptions with respect to future events regarding its business, including other statements with respect to the Company’s plans, assumptions, expectations, beliefs and objectives, the success of the Company’s current and future business strategies, product development, pre-clinical studies, clinical studies, clinical and regulatory timelines, market opportunity, competitive position, business strategies, potential growth and financing opportunities and other statements that are predictive in nature. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to the Company on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including risks related to the initiation, design, timing, enrollment, and conduct of clinical trials and interactions with regulatory authorities, and risks that future clinical trial results may not match results observed to date, may be negative or ambiguous, or may not reach the level of statistical significance required for regulatory approval, as well as other factors set forth in the Company’s most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q and other filings made with the U.S. Securities and Exchange Commission (SEC). Thus, actual results could be materially different. The Company undertakes no obligation to update these statements whether as a result of new information, future events or otherwise, after the date of this release, except as required by law.

 

Contact

 

Company Contact:

 

Patrick Gaynes

Corporate Communications

pgaynes@pasithea.com

 

For Investor Inquiries:

 

Mike Moyer

Managing Director, LifeSci Advisors, LLC

mmoyer@lifesciadvisors.com

 

6

Filing Exhibits & Attachments

4 documents

Keep reading